FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034143679> ?p ?o ?g. }

• W2034143679 endingPage "488" @default.
• W2034143679 startingPage "488" @default.
• W2034143679 abstract "To the Editor: We were surprised that, in the systematic review and meta-analysis on the effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation, the authors considered triflusal in the same group as indobufen and aspirin, as they also inhibit the cyclooxygenase (COX)-1 enzyme (1). Although this is true, some pharmacological differences between these agents and some important evidence-based clinical differences between triflusal and aspirin should be considered. With respect to pharmacological differences, it should be mentioned that the COX-1 inhibition by aspirin is irreversible (2) whereas the inhibition by indobufen is reversible (3). Concerning triflusal, it should be taken into account that this agent is an irreversible inhibitor of COX-1, whereas its active metabolite 2-hydroxy-4-(trifluo-romethyl) benzoic acid (HTB) is a reversible inhibitor of the enzyme (4). Triflusal has little influence on vascular endothelial prostacyclin production, thus potentially preserving the favourable vasodilatory and platelet anti-aggregatory effects of prostacyclin. Conversely, aspirin reduces both thromboxane and prostacyclin release, thus reducing the favourable vascular effects of prostacyclin (4). Lastly, triflusal, but not aspirin, inhibits cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) phosphodiesterase, and therefore cAMP and cGMP breakdown in platelets, thus inhibiting calcium mobilisation and calcium-dependent platelet aggregation (4). Triflusal has not been compared with indobufen, but the available evidence from randomised clinical trials (5-7) demonstrates that triflusal has an efficacy similar to aspirin to prevent serious vascular events, but with a lower haemorrhagic risk, in patients with acute myocardial infarction (5) and ischaemic stroke or transient ischaemic attack (TIA) (6, 7). These results have been confirmed in a meta-analysis (8). Moreover, in The Triflusal vs. Aspirin in Cerebral Infarction Prevention (TACIP) Study (6), comparing triflusal against aspirin in 2107 patients with ischaemic stroke or TIA, the incidence of gastrointestinal haemorrhage was 7.6% in the aspirin group and 4.6% in the triflusal group (p = 0.005). A meta-analysis in 5169 patients with acute myocardial infarction or ischaemic stroke or TIA (8) showed that the risk of gastrointestinal haemorrhage is lower with triflusal than with aspirin (OR for aspirin vs. triflusal: 1.83; 95% CI: 1.35–2.48), and in two case-control studies it was reported that the risk of upper gastrointestinal bleeding associated with triflusal is negligible, whereas the risk associated with the use of aspirin is clear (9, 10). Concerning patients with atrial fibrillation, the National Study for Prevention of Embolism in Atrial Fibrillation (NASPEAF) (10) showed that the addition of triflusal to reduced-intensity anticoagulation in patients with atrial fibrillation, stratified for risk of thromboembolism, significantly decreases subsequent vascular events compared with standard anticoagulation, and does so without increasing neither systemic nor gastrointestinal bleeding risk. The clinical benefit of the association of triflusal with reduced-intensity anticoagulation in patients with atrial fibrillation has not been shown neither with aspirin (12-14) nor with another other antiplatelet drug. In our opinion, all the above are important reasons to distinguish triflusal from aspirin and indobufen in a meta-analysis on gastrointestinal bleeding in patients with atrial fibrillation. Javier Borja and Alejandro Doménech are employees of Vifor Pharma Spain, S.L., the Company that markets triflusal in Spain. Julián García-Rafanell is employee of J. Uriach y Compañia, S.A., the Company that markets triflusal in other countries." @default.
• W2034143679 created "2016-06-24" @default.
• W2034143679 creator A5029343992 @default.
• W2034143679 creator A5054830031 @default.
• W2034143679 creator A5042175867 @default.
• W2034143679 date "2013-02-27" @default.
• W2034143679 modified "2023-10-16" @default.
• W2034143679 title "Pharmacological therapies and major gastrointestinal bleeding in patients with atrial fibrillation" @default.
• W2034143679 cites W1704466199 @default.
• W2034143679 cites W1987034302 @default.
• W2034143679 cites W1988493325 @default.
• W2034143679 cites W2004786986 @default.
• W2034143679 cites W2017544087 @default.
• W2034143679 cites W2018457967 @default.
• W2034143679 cites W2019799671 @default.
• W2034143679 cites W2091136930 @default.
• W2034143679 cites W2135936852 @default.
• W2034143679 cites W2149441868 @default.
• W2034143679 cites W44202489 @default.
• W2034143679 doi "https://doi.org/10.1111/j.1742-1241.2012.02976.x" @default.
• W2034143679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23445436" @default.
• W2034143679 hasPublicationYear "2013" @default.
• W2034143679 type Work @default.
• W2034143679 sameAs 2034143679 @default.
• W2034143679 citedByCount "1" @default.
• W2034143679 countsByYear W20341436792020 @default.
• W2034143679 crossrefType "journal-article" @default.
• W2034143679 hasAuthorship W2034143679A5029343992 @default.
• W2034143679 hasAuthorship W2034143679A5042175867 @default.
• W2034143679 hasAuthorship W2034143679A5054830031 @default.
• W2034143679 hasConcept C126322002 @default.
• W2034143679 hasConcept C177713679 @default.
• W2034143679 hasConcept C2778080469 @default.
• W2034143679 hasConcept C2779161974 @default.
• W2034143679 hasConcept C71924100 @default.
• W2034143679 hasConceptScore W2034143679C126322002 @default.
• W2034143679 hasConceptScore W2034143679C177713679 @default.
• W2034143679 hasConceptScore W2034143679C2778080469 @default.
• W2034143679 hasConceptScore W2034143679C2779161974 @default.
• W2034143679 hasConceptScore W2034143679C71924100 @default.
• W2034143679 hasIssue "5" @default.
• W2034143679 hasLocation W20341436791 @default.
• W2034143679 hasLocation W20341436792 @default.
• W2034143679 hasOpenAccess W2034143679 @default.
• W2034143679 hasPrimaryLocation W20341436791 @default.
• W2034143679 hasRelatedWork W1967841144 @default.
• W2034143679 hasRelatedWork W2018480046 @default.
• W2034143679 hasRelatedWork W2248265101 @default.
• W2034143679 hasRelatedWork W2312606134 @default.
• W2034143679 hasRelatedWork W2319489406 @default.
• W2034143679 hasRelatedWork W2333279585 @default.
• W2034143679 hasRelatedWork W2603808924 @default.
• W2034143679 hasRelatedWork W2793053827 @default.
• W2034143679 hasRelatedWork W2889073610 @default.
• W2034143679 hasRelatedWork W4241831378 @default.
• W2034143679 hasVolume "67" @default.
• W2034143679 isParatext "false" @default.
• W2034143679 isRetracted "false" @default.
• W2034143679 magId "2034143679" @default.
• W2034143679 workType "article" @default.